Identification of exon 19 and 21 mutations of EGFR gene in Chinese patients with esophageal squamous cell carcinoma

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Cui, Yong ^a   Chang, Dong ^a   Liu, Mingliang ^a   Lin, Changjin ^a   Zhao, Baojian ^b   Zhang, Xu ^b   Gong, Min ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b AIR FORCE GENERAL HOSPITAL   (China)

Author keywords

Denaturing high performance liquid chromatography; Epidermal growth factor receptor; Esophageal squamous cell carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ARTICLE; CODON; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; EXON; GENE DELETION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NUCLEIC ACID BASE SUBSTITUTION;

ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; EXONS; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION;

EID: 84885065835     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-266     Document Type: Article

References (26)

1. Zhang J, Dhakal IB, Zhao Z, Li L. Trends in mortality from cancers of the breast, colon, prostate, esophagus, and stomach in East Asia: role of nutrition transition. Eur J Cancer Prev 2012, 21:480-489. 10.1097/CEJ.0b013e328351c732, 22357483.
2. Jin J, Xu X, Wang F, Yan G, Liu J, Lu W, Li X, Tucker SJ, Zhong B, Cao Z, Wang D. Second-line combination chemotherapy with docetaxel and nedaplatin for cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma. J Thorac Oncol 2009, 4:1017-1021. 10.1097/JTO.0b013e3181add9c7, 19542899.
3. Park BB, Im YH, Hwang IG, Lee SC, Ahn JS, Ahn MJ, Lim HY, Kang WK, Park K. Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. Invest New Drugs 2008, 26:387-392. 10.1007/s10637-008-9126-3, 18368291.
4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139. 10.1056/NEJMoa040938, 15118073.
5. Zhang GC, Lin JY, Wang Z, Zhou Q, Xu CR, Zhu JQ, Wang K, Yang XN, Chen G, Yang JJ, Huang YJ, Liao RQ, Wu YL. Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients. Clin Oncol (R Coll Radiol) 2007, 19:499-506. 10.1016/j.clon.2007.04.006, 17537621.
6. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 2013
7. Zhu CQ, Da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, Tsao MS. National Cancer Institute of Canada Clinical Trials Group Study BR.21 Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26:4268-4275. 10.1200/JCO.2007.14.8924, 18626007, National Cancer Institute of Canada Clinical Trials Group Study BR.21.
8. Finberg KE, Sequist LV, Joshi VA, Muzikansky A, Miller JM, Han M, Beheshti J, Chirieac LR, Mark EJ, Iafrate AJ. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 2007, 9:320-326. 10.2353/jmoldx.2007.060182, 1899415, 17591931.
9. Rodriguez CP, Adelstein DJ, Rice TW, Rybicki LA, Videtic GM, Saxton JP, Murthy SC, Mason DP, Ives DI. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol 2010, 5:229-235. 10.1097/JTO.0b013e3181c5e334, 20009775.
10. Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, Perez ML, Soriano JL, Gonzalez CE, Hernadez IM, Albuerne YA, Moreno BP, Alvarez ES, Callejo IP, Alert J, Martell JA, Gonzalez YS, Gonzalez YS, Astudillo de la Vega H, Ruiz-Garcia EB, Ramos TC. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther 2012, 13:600-605. 10.4161/cbt.19849, 22555809.
11. Xu Y, Sheng L, Mao W. Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action. Oncol Lett 2013, 5:19-24. 3525339, 23255886.
12. Puhringer-Oppermann FA, Stein HJ, Sarbia M. Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas. Dis Esophagus 2007, 20:9-11. 10.1111/j.1442-2050.2007.00630.x, 17227303.
13. Sudo T, Mimori K, Nagahara H, Utsunomiya T, Fujita H, Tanaka Y, Shirouzu K, Inoue H, Mori M. Identification of EGFR mutations in esophageal cancer. Eur J Surg Oncol 2007, 33:44-48. 10.1016/j.ejso.2006.10.034, 17142003.
14. Mir MM, Dar NA, Salam I, Shah ZA. Mutations in epidermal growth factor receptor gene in esophageal squamous cell carcinoma patients in Kashmir- a high incidence area of India. Int J Health Sci (Qassim) 2008, 2:17-25. 3068730, 21475485.
15. Kaneko K, Kumekawa Y, Makino R, Nozawa H, Hirayama Y, Kogo M, Konishi K, Katagiri A, Kubota Y, Muramoto T, Kushima M, Ohmori T, Oyama T, Kagawa N, Ohtsu A, Imawari M. EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. Front Biosci 2010, 15:65-72.
16. Liu QW, Fu JH, Luo KJ, Yang HX, Wang JY, Hu Y, Yang H, Bella E. Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma. Dis Esophagus 2011
17. Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 1976, 3:2303-2308. 10.1093/nar/3.9.2303, 343085, 987581.
18. Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009, 27:2653-2659. 10.1200/JCO.2008.17.3930, 19414683.
19. Asano H, Toyooka S, Tokumo M, Ichimura K, Aoe K, Ito S, Tsukuda K, Ouchida M, Aoe M, Katayama H, Hiraki A, Sugi K, Kiura K, Date H, Shimizu N. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 2006, 12:43-48. 10.1158/1078-0432.CCR-05-0934, 16397022.
20. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. National Cancer Institute of Canada Clinical Trials Group Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-1966. 10.1200/JCO.2006.07.9525, 17452677, National Cancer Institute of Canada Clinical Trials Group.
21. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, Van Groeningen C, Giaccone G. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006, 24:1612-1619. 10.1200/JCO.2005.03.4900, 16575012.
22. Wang WP, Wang KN, Gao Q, Chen LQ. Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction. World J Surg Oncol 2012, 10:14. 10.1186/1477-7819-10-14, 3278359, 22252115.
23. Tasioudi KE, Saetta AA, Sakellariou S, Levidou G, Michalopoulos NV, Theodorou D, Patsouris E, Korkolopoulou P. pERK activation in esophageal carcinomas: clinicopathological associations. Pathol Res Pract 2012, 208:398-404. 10.1016/j.prp.2012.05.009, 22658382.
24. Gonzaga IM, Soares-Lima SC, de Santos PT, Blanco TC, de Reis BS, Quintella DC, de Oliveira IM, de Faria PA, Kruel CD, Andreollo NA, de Simão TA, Pinto LF. Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas. BMC Cancer 2012, 12:569. 10.1186/1471-2407-12-569, 3537527, 23207070.
25. Lyronis ID, Baritaki S, Bizakis I, Krambovitis E, Spandidos DA. K-ras mutation, HPV infection and smoking or alcohol abuse positively correlate with esophageal squamous carcinoma. Pathol Oncol Res 2008, 14:267-273. 10.1007/s12253-008-9032-1, 18592405.
26. Shigaki H, Baba Y, Watanabe M, Miyake K, Murata A, Iwagami S, Ishimoto T, Iwatsuki M, Yoshida N, Baba H. KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review. Ann Surg Oncol 2012